The Guangdong, China–based generics manufacturer and its commercialization partner Lanexa Biologics received FDA approval for their insulin glargine biosimilar Langlara. In addition to its insulin glargine product, which is approved in China, other biosimilars may follow based on Sunshine Lake’s other existing insulin formulations. Another insulin glargine biosimilar has joined the ranks of Semglee and … Continue reading Sunshine Lake Pharma and Lanexa Biologics Get Their First FDA Biosimilar Approval